Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases

Z Detkova, PBF Mensink, Jan Dees, Ernst Kuipers, C.J. van der Woude

Research output: Contribution to journalArticleAcademicpeer-review

27 Citations (Scopus)


Objective. Inflammatory bowel disease (11313) affects patients in reproductive age but little is known about the peri-conceptional use of medication for IBD. The aim of this study was to assess the type of medication used by 11313 patients with the desire to reproduce and changes in medication in the peri-conceptional period. Material and methods. 11313 patients with active conception plans and pregnant patients were prospectively recruited from the outpatient clinic of a single academic medical center. IBD-related medication and changes in this medication for reasons of a desire to conceive or pregnancy were analyzed. Results. In total, 61 patients (51 females; 40 with Crohn's disease, 21 with ulcerative colitis) were included. Thirteen patients (21%) used no medication, 44 (72%) used monotherapy and four (7%) used combination treatment. Of patients on monotherapy, 11 (19%) used 5-aminosalicylates, five (9%) used steroids, 11 (19%) used thiopurines, five (9%) used methotrexate and 11 (19%) used anti-tumor necrosis factor agents. Thirty-seven patients (61%) consulted a physician prior to conception. About one-third of these patients required a change in their medication due to their conception plans. Conclusions. In a referral center, the majority of IBD patients with conception plans require medication for which limited information on the safety of peri-conceptional use is available. In addition, the desire to reproduce leads to medication changes in about one-third of these patients.
Original languageUndefined/Unknown
Pages (from-to)46-50
Number of pages5
JournalScandinavian Journal of Gastroenterology
Issue number1
Publication statusPublished - 2010

Research programs

  • EMC MM-04-20-01

Cite this